Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|21|35|4013-4045

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.35, 2014-01, pp. : 4013-4045

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment

By  

Current Drug Targets, Vol. 15, Iss. 6, 2014-06 ,pp. : 600-621

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

By  

Current Drug Targets, Vol. 10, Iss. 1, 2009-01 ,pp. : 71-87

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase-IV (DPP-IV) inhibitors enhance the paracrine antilipolytic effects of neuropeptide Y (NPY)

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Docking Study of Novel Pyrrolidine Derivatives as Potential Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 12, Iss. 4, 2015-05 ,pp. : 284-291

Bentham Science Publishers

Access to resources Recommend Favorite